How to Use the Program

The HEMLIBRA Co-pay Program may be used in a community practice, hemophilia treatment center, hospital, or specialty pharmacy.

Participating practices, institutions or specialty pharmacies must complete a onetime registration so they may process HEMLIBRA Co-pay Program payments. To register, call (844) HEM-COPAY (844-436-2672).

THE PROVIDER sends the prescription. Either the provider or patient sends the patient's processing information including their group number, RxBIN, PCN and member ID numbers to the hemophilia treatment center (HTC) pharmacy or specialty pharmacy (SP).
THE HTC PHARMACY OR SP collects the patient's co-pay.
THE HTC PHARMACY OR SP uses the group number, RxBIN and PCN to process the HEMLIBRA Co-pay Program as secondary insurance and ships HEMLIBRA to the patient.
THE HEMLIBRA CO-PAY PROGRAM reimburses the HTC pharmacy or SP for the patient's out-of-pocket costs for HEMLIBRA up to the annual program limit.
Indication and Important Safety Information



HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A with or without factor VIII inhibitors.

Important Safety Information


Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur.

Warnings and Precautions

  • Immunogenicity: Anti-emicizumab antibodies (including neutralizing antibodies) have developed in HEMLIBRA-treated patients
  • In case of clinical signs of loss of efficacy, promptly assess the etiology and consider a change in treatment if neutralizing antibodies are suspected
  • Laboratory coagulation test interference: HEMLIBRA interferes with activated clotting time (ACT); activated partial thromboplastin time (aPTT); and coagulation laboratory tests based on aPTT, including one-stage, aPTT-based single-factor assays; aPTT-based Activated Protein C Resistance (APC-R); and Bethesda assays (clotting-based) for factor VIII (FVIII) inhibitor titers. Intrinsic pathway clotting-based laboratory tests should not be used

Most Common Adverse Reactions

The most common adverse reactions (incidence ≥10%) are injection site reactions, headache, and arthralgia.

You may report side effects to the FDA at (800) FDA-1088 or You may also report side effects to Genentech at (888) 835-2555.

Please see the HEMLIBRA full Prescribing Information for additional Important Safety Information, including Boxed WARNING.